Lucid Capital initiated coverage of Medicenna Therapeutics (MDNAF) with a Buy rating and C$4 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDNAF:
- Promising Developments in Medicenna Therapeutics Corp’s ABILITY-1 Trial Justify Buy Rating
- Medicenna to Engage Investors at ROTH Healthcare Conference
- Medicenna Therapeutics Announces Shareholder Meeting Results and Leadership Updates
- Medicenna to Present at H.C. Wainwright Global Investment Conference